The drugs were compared to standard care for hospital patients.
The WHO said in a press release that it “accepted” the recommendation from the International Steering Committee to discontinue the trial of hydroxychloroquine and the HIV / AIDS drugs lopinavir and ritonavir, as this could not reduce COVID-19 mortality.
The World Health Organization announced on Saturday that it will end a trial of the hydroxychloroquine malaria drug that President Trump has widely touted as a miracle cure, although a new study found that coronavirus patients are 50 percent less likely to die.
The move follows the National Institute of Health, which stopped clinical trials with hydroxychloroquine as a coronavirus treatment in hospital in June.
“Investigators of solidarity studies will interrupt the processes with immediate effect,” said the WHO in a statement referring to large multi-country processes led by the agency.
Do me a favor: Please SHARE this post.
“These interim results show that hydroxychloroquine and lopinavir / ritonavir barely, or not at all, reduce the mortality rate of COVID-19 patients in hospital compared to the standard of care,” said a press release.
Health officials at the NIH “found that the study drug did no harm, but was very unlikely for hospitalized patients with COVID-19.”
In addition, the FDA again warned that hydroxychloroquine should not be used to treat coronaviruses outside of the hospital environment or in a clinical trial because of the risk of irregular heartbeat.
The agency had previously revoked its emergency approval, which allowed the drug to be used in hospitals.
He has been repeatedly criticized for squeezing hydroxychloroquine, while a number of health experts and officials have pointed out that there is growing evidence of the drug’s apparent errors.
President Trump spent much of the coronavirus pandemic announcing hydroxychloroquine as a serious medical candidate during daily briefings and press conferences.
However, this contradicts a recent study by the Henry Ford Health System that found coronavirus patients who were treated early with hydroxychloroquine were 50 percent less likely to die.
The first study started with five branches that looked at possible treatments for COVID-19: standard care; remdesivir; Hydroxychloroquin; Lopinavir / Ritonavir; and lopanivir / ritonavir combined with interferon.
The WHO said the decision had no effect on possible studies with patients who were not hospitalized or with those who received the medication before or soon after exposure to the coronavirus.
The WHO added that while there was no “solid evidence” of increased mortality in hospitalized patients receiving the medication, there was “some associated safety signals in clinical laboratory findings” from an associated study.
Mike Ryan, WHO’s leading emergency expert, said Friday that it was unwise to predict when a vaccine could be ready.
Among nearly 150 treatments in development, 18 experimental COVID-19 vaccines are being tested on humans.
WHO Director General, Tedros Adhanom Ghebreyesus, told reporters on Friday that nearly 5,500 patients in 39 countries have been recruited for their clinical trials to date, and interim results are expected within two weeks.
While a vaccine candidate could show its effectiveness by the end of the year, the question was how quickly it could be mass-produced, he said.
However, the recent Henry Ford Health System study suggests that hydroxychloroquine could be a real contender to help coronavirus patients.
The new study, published in the International Journal of Infectious Diseases, included more patients under the age of 65 and a more racially diverse group.
Whether it was timing or something else, the results of the new study were drastically different.
Henry Ford researchers argued that this was a great advantage over the recent New York state study on hydroxychloroquine, although patients who took part received the drug on average one day after admission (patients could be included if they went to any one Would be dosed at the time of their hospital stay ‘).
More than 80 percent received hydroxychloroquine within 24 hours of hospitalization, and 91 percent received the drug within 48 hours.
Please share this post
–
